Tecan US
Launches Safire2 Microplate Reader at Lab Automation 2004
February 2004 (Newstream) -- Tecan US, a
leader in the Life Sciences supply industry, today introduced Safire2, a fully
modular monochromator-based microplate detection system with a full range of high speed
fluorescence techniques. Safire2 enables high throughput screening and assay
development to be performed on one instrument.
Carl Severinghaus, President, Tecan US
remarked, "Safire2 was developed to meet the needs of today's drug
discovery laboratories that require speed, sensitivity and flexibility. The industry has
been eagerly waiting for a time and cost-saving automation solution like Safire2
that eliminates the need to switch instruments when moving from assay development to high
throughput screening."
With Safire2, detection
modules are available for top and bottom fluorescence intensity measurements, fluorescence
polarization studies and multi-channel absorbance and luminescence measurements. This
microplate detection system has a variety of options to fit application requirements, and
will enable researchers to perform the latest biomolecular assays for primary or secondary
screening, such as molecular interaction assays, kinase assays, protease assays or highly
sensitive G-protein-coupled receptor assays. Another key feature is that consecutive
measurements in different fluorescent modes may be made with the shortest possible time
interval between measurements.
Safire2 does not require a
time-consuming filter change, and all of the wavelengths are easily accessible through a
specially designed fast-scanning monochromator. Safire2 is easily combined with
a stacker module that allows rapid processing of up to 50 microplates. Through easy
integration into Tecan's Freedom EVO series platforms, users also have access to fully
automated drug discovery platforms.
About Tecan
Tecan (www.tecan.com) is a leading player in the Life Sciences supply
industry that specializes in the development, production, and distribution of solutions
enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics,
and diagnostics. Tecan clients are leading pharmaceutical and biotechnology companies,
university research departments and diagnostic laboratories. Founded in Switzerland in
1980, the company has manufacturing, research and development sites in both North America
and Europe and maintains a sales and service network in 52 countries. In 2002, Tecan
achieved sales of CH 332.2 million (USD 212.9 million; EUR 226.0 million). Registered
shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S /
Valor : 1210019).
Site navigation
